<?xml version="1.0" ?><ns2:com.thomsonreuters.ls.service.contract.soap.drugs.v2.DrugRecordOutput xmlns:ns2="local" id="70625"><DrugName>Hemporfin photodynamic therapy (port wine stain), Shanghai Fudan-Zhangjiang Bio-Pharmaceutical</DrugName><DrugNamesKey><Name id="43025244">FMD</Name><Name id="43022345">FuMeiDa</Name><Name id="42948659">Hemporfin</Name></DrugNamesKey><DrugSynonyms><Name><Value>hematoporphyrin monomethyl ether</Value></Name><Name><Value>Hemporfin photodynamic therapy (port wine stain), Shanghai Fudan-Zhangjiang Bio-Pharmaceutical</Value></Name><Name><Value>Hemoporfin</Value></Name><Name><Value>Hemporfin</Value><Types><Type>Trade Name</Type></Types></Name><Name><Value>HMME</Value></Name><Name><Value>FuMeiDa</Value><Types><Type>Trade Name</Type></Types></Name><Name><Value>FMD</Value><Types><Type>Trade Name</Type></Types></Name></DrugSynonyms><CompanyOriginator id="1012768">Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd</CompanyOriginator><CompaniesPrimary><Company id="1012768">Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd</Company></CompaniesPrimary><CrossReferences><SourceEntity id="1012768" type="Company"><TargetEntity id="4295863943" type="organizationId">Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd</TargetEntity></SourceEntity><SourceEntity id="3841" type="ciIndication"><TargetEntity id="D019339" type="MeSH"></TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="L">Launched</PhaseHighest><PhaseHighestDetailed><FirstLaunched>Port wine stain - China - Dec-2016</FirstLaunched></PhaseHighestDetailed><RegulatoryDesignations><RegulatoryDesignation id="18">National Science and Technology Major Project</RegulatoryDesignation><RegulatoryDesignation id="19">Special Review Project</RegulatoryDesignation></RegulatoryDesignations><IndicationsPrimary><Indication id="3841">Port wine stain</Indication></IndicationsPrimary><ActionsSecondary><Action id="1880">Dermatological agent</Action><Action id="799">Photosensitizer</Action></ActionsSecondary><Technologies><Technology id="648">Intravenous formulation</Technology><Technology id="762">Small molecule therapeutic</Technology></Technologies><LastModificationDate>2019-03-22T08:05:46.000Z</LastModificationDate><ChangeDateLast>2017-10-24T00:00:00.000Z</ChangeDateLast><AddedDate>2011-03-25T10:43:23.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="1012768" linkType="Company"&gt;Shanghai Fudan-Zhangjiang Bio-Pharmaceutical&lt;/ulink&gt;  has developed  and launched FuMeiDa (FMD), a photodynamic therapy (PDT) using Hemporfin (Hemoporfin, hematoporphyrin monomethyl ether, HMME) for the iv treatment of port wine stain [&lt;ulink linkID="1171021" linkType="Reference"&gt;1171021&lt;/ulink&gt;], [&lt;ulink linkID="1179071" linkType="Reference"&gt;1179071&lt;/ulink&gt;], [&lt;ulink linkID="1497783" linkType="Reference"&gt;1497783&lt;/ulink&gt;], [&lt;ulink linkID="1509133" linkType="Reference"&gt;1509133&lt;/ulink&gt;]. In  Decemeber 2016,   the product  was launched [&lt;ulink linkID="1882105" linkType="Reference"&gt;1882105&lt;/ulink&gt;]. By February 2019, an NDA application was planned  in the US [&lt;ulink linkID="2132043" linkType="Reference"&gt;2132043&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary><Regulatory><displayLabel>Regulatory</displayLabel><value>&lt;Regulatory&gt;&lt;para&gt;In December 2010, an NDA for the drug as a class 1.1 chemical drug was filed in China; at that time, the application was listed as "Special Review Project" and "National Science and Technology Major Project" [&lt;ulink linkID="1973683" linkType="Reference"&gt;1973683&lt;/ulink&gt;]. In  January 2013, the application was approved  [&lt;ulink linkID="1608175" linkType="Reference"&gt;1608175&lt;/ulink&gt;]. At that time, the GMP certificate had not yet been obtained and no launch date was confirmed [&lt;ulink linkID="1358083" linkType="Reference"&gt;1358083&lt;/ulink&gt;]. By February  2013, the drug received a New Drug Certificate in China [&lt;ulink linkID="1400382" linkType="Reference"&gt;1400382&lt;/ulink&gt;].   In November 2013, the therapy was expected to launch in 2014 [&lt;ulink linkID="1497783" linkType="Reference"&gt;1497783&lt;/ulink&gt;]; In August 2014, the therapy was expected to launch in the first half of 2015 [&lt;ulink linkID="1586781" linkType="Reference"&gt;1586781&lt;/ulink&gt;]. In August 2015, the application was in  reviewing stage   [&lt;ulink linkID="1687986" linkType="Reference"&gt;1687986&lt;/ulink&gt;]. In March 2016, launch was expected in the second half of 2016 [&lt;ulink linkID="1745030" linkType="Reference"&gt;1745030&lt;/ulink&gt;]. In  Decemeber 2016,  the product  was launched [&lt;ulink linkID="1882105" linkType="Reference"&gt;1882105&lt;/ulink&gt;]. By February 2019, an NDA application was planned  in the US [&lt;ulink linkID="2132043" linkType="Reference"&gt;2132043&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regulatory&gt;</value></Regulatory><Premarketing><displayLabel>Premarketing</displayLabel><value>&lt;Premarketing&gt;&lt;para&gt;By March 2011, a phase III trial had been completed [&lt;ulink linkID="1179071" linkType="Reference"&gt;1179071&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In January 2011, data from a phase IIa, 8-week open-label, 40-patient trial were published, showing that Hemporfin PDT was effective and safe [&lt;ulink linkID="1179215" linkType="Reference"&gt;1179215&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In December 2008, a randomized, multicentre, double-blind, placebo-controlled and parallet group phase III trial (&lt;ulink linkID="92402" linkType="Protocol"&gt;ChiCTR-TRC-08000213&lt;/ulink&gt;) was started to evaluate efficacy and safety of hemoporfin in photodynamic therapy for patients (n = 440) with port-wine stain [&lt;ulink linkID="1400381" linkType="Reference"&gt;1400381&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In October 2007, a randomized, double-blind, placebo-controlled, parallel group, multicenter, phase IIb study (&lt;ulink linkID="91686" linkType="Protocol"&gt;ChiCTR-TRC-08000233&lt;/ulink&gt;) was initiated in China to determine the appropriate doses of hemoporfin in photodynamic therapy for port-wine stain patients on the basis of phase IIa study. In August 2008, the trial was completed [&lt;ulink linkID="1608177" linkType="Reference"&gt;1608177&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In October 2006, a randomized, double-blind, placebo-controlled, parallel group, multicenter, phase IIa study (&lt;ulink linkID="91579" linkType="Protocol"&gt;ChiCTR-TRC-08000236&lt;/ulink&gt;) was initiated in China to determine the appropriate laser exposure time of hemoporfin photodynamic therapy for port-wine stain patients (n = 40). In October 2007, the trial was completed [&lt;ulink linkID="1608176" linkType="Reference"&gt;1608176&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In January 2005, an IND was filed in China [&lt;ulink linkID="1608174" linkType="Reference"&gt;1608174&lt;/ulink&gt;]. By the end of 2005, the SFDA had approved trials of the drug [&lt;ulink linkID="1171021" linkType="Reference"&gt;1171021&lt;/ulink&gt;].&lt;/para&gt;&lt;/Premarketing&gt;</value></Premarketing><AdditionalInformation><displayLabel>Additional Information</displayLabel><value>&lt;AdditionalInformation&gt;&lt;para&gt;The program was listed as ‘Major Drug Discovery Project’ in China's 12th 5-year plan [&lt;ulink linkID="1400382" linkType="Reference"&gt;1400382&lt;/ulink&gt;].&lt;/para&gt;&lt;/AdditionalInformation&gt;</value></AdditionalInformation></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="1012768">Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd</Company><Country id="CN">China</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3841">Port wine stain</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2016-12-03T00:00:00.000Z</StatusDate><Source id="1882105" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1012768">Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="3841">Port wine stain</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2019-02-28T00:00:00.000Z</StatusDate><Source id="2132043" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="1012768">Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd</Company><Country id="CN">China</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="3841">Port wine stain</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2010-12-28T00:00:00.000Z</StatusDate><Source id="1608175" type="OTHER"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1012768">Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd</Company><Country id="CN">China</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="3841">Port wine stain</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2008-09-01T00:00:00.000Z</StatusDate><Source id="1400381" type="SERIAL"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1012768">Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd</Company><Country id="CN">China</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="3841">Port wine stain</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2006-10-01T00:00:00.000Z</StatusDate><Source id="1608176" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1012768">Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd</Company><Country id="CN">China</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="3841">Port wine stain</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2005-01-04T00:00:00.000Z</StatusDate><Source id="1608174" type="OTHER"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1012768">Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd</Company><Country id="CN">China</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="3841">Port wine stain</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2013-01-10T00:00:00.000Z</StatusDate><Source id="1608175" type="OTHER"></Source></DevelopmentStatusHistoric></IDdbDevelopmentStatus><RegulatoryDesignationStatus><Row><RegulatoryDesignation id="18">National Science and Technology Major Project</RegulatoryDesignation><OwnerCompany id="1012768">Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd</OwnerCompany><Country id="CN">China</Country><Indication id="3841">Port wine stain</Indication><AwardedIndication>Port wine stain</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2010-10-28T00:00:00.000Z</MileStoneDate><Source id="1973683" type="OTHER"></Source></Row><Row><RegulatoryDesignation id="19">Special Review Project</RegulatoryDesignation><OwnerCompany id="1012768">Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd</OwnerCompany><Country id="CN">China</Country><Indication id="3841">Port wine stain</Indication><AwardedIndication>Port wine stain</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2010-10-28T00:00:00.000Z</MileStoneDate><Source id="1973683" type="OTHER"></Source></Row></RegulatoryDesignationStatus><ReasonsForUpdate><ReasonForUpdate><Reason>Editorial Amendments</Reason><Description>Minor editorial amendment</Description></ReasonForUpdate></ReasonsForUpdate><StructureSmiles><Smiles>Cc1c2/cc/3\nc(/cc\4/c(c(/c(/[nH]4)c/c5n/c(c\c(c1CCC(=O)O)[nH]2)/C(=C5C)CCC(=O)O)C)C(C)OC)C(=C3C(C)O)C.Cc1c2/cc/3\nc(/cc\4/c(c(/c(/[nH]4)c/c5n/c(c\c(c1CCC(=O)O)[nH]2)/C(=C5C)CCC(=O)O)C)C(C)O)C(=C3C(C)OC)C</Smiles></StructureSmiles><PatentFamilies><PatentFamily id="817160" number="US-20120029045" title="Method for treating port wine stains"></PatentFamily></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="14">Tentative</Type><Count>1</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd" id="1012768"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>N</hasSWOTs></ns2:com.thomsonreuters.ls.service.contract.soap.drugs.v2.DrugRecordOutput>